ow Dose Atomoxetine in Cardiovascular Disease: A Pilot Study

• Conditions: hypertension; hypercholesterolaemia; diabetes; Stress/anxiety; Overweight/obesity; Cardiovascular - Hypertension; Mental Health - Anxiety; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12615000376549
• Lead Sponsor: Professor Simon Dimmitt

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

currently prescribed medication to treat hypertension, hypercholesterolaemia or diabetes; or have previously suffered an arterial clinical event such as angina, acute myocardial infarction, transient ischemic event, stroke or retinal infarct/haemorrhage; and have a body mass index of greater than 25; and elevated DASS sub scale score (stress > 4, anxiety > 4 or depression > 4)

Exclusion Criteria

unstable physical illness, clinical and/or questionnaire evidence of major psychiatric disorder and/or patients currently on psychotropic medication, a DASS score > 21, patients with atrial fibrillation or blood pressure > 170/110

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stress/anxiety levels; Proportion of participants with a reduction in stress/anxiety; measured by Depression Anxiety Stress Scales (DASS) & Spielberger Questionnaire.[18 weeks]

Secondary Outcome Measures

Name	Time	Method
Cardiovascular risk (this is a composite secondary outcome); Proportion of participants with a reduction in weight (kg measured by scales), blood pressure (mmHg measured on an automatic sphygmomanometer), blood cholesterol (serum assay) and glucose (serum assay).[18 weeks ]